The utilization of dabrafenib and trametinib as therapeutic approaches for anaplastic thyroid carcinoma characterized by the presence of the BRAF V600E mutation represented a novel strategy that exhibited good clinical efficacy and favorable tolerability. Here, BRAF is linked to thyroid gland undifferentiated (anaplastic) carcinoma.